All In Biotech

Drug Trial Radar · NCT02486627

A Study of Plazomicin Compared With Meropenem for the Treatment of Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis (AP)

A Phase 3, Randomized, Multicenter, Double-Blind Study to Evaluate the Efficacy and Safety of Plazomicin Compared With Meropenem Followed by Optional Oral Therapy for the Treatment of Complicated Urinary Tract Infection (cUTI), Including Acute Pyelonephritis (AP), in Adults

Last checked: Nov 20, 2026Latest source record: Aug 23, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 609 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

609

Actual

Start

Jan 11, 2016

Primary completion

Sep 22, 2016

Study completion Sep 22, 2016

Sponsor

Lead sponsor
Achaogen, Inc.Industry
Sponsor type
Industry
First posted
Jul 1, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was a randomized, multicenter, multinational, double-blind study comparing the efficacy and safety of plazomicin compared with meropenem followed by optional oral (PO) therapy in the treatment of cUTI, including AP, in adults.

Conditions

  • Complicated Urinary Tract Infection
  • Acute Pyelonephritis

Interventions

  • plazomicinDrug

  • meropenemDrug

  • levofloxacin (oral)Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Patients With Composite of Microbiological Eradication and Clinical Cure in the Microbiological Modified ITT (mMITT) Population at Day 5Time frame: Day 5
  2. Percentage of Patients With Composite of Microbiological Eradication and Clinical Cure in the mMITT Population at Test of Cure (TOC)Time frame: Day 17 TOC Visit

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.